During the conference call on March 16, 2015 discussing 4Q, 2014 results, management announced that it had decided to…
Discovery Laboratories: Delay in Completion of Aerosurf Phase 2a Trial and Continued Disappointing Sales of Surfaxin Weigh on the Stock (DSCO, $1.53, Hold)
Phase 2a Aerosurf trial completion has been pushed back to 1Q, 2015 from 4Q, 2014.
Discovery Laboratories: My Current Thinking on the Surfaxin Launch and Aerosurf Phase 2 Trials (DSCO, Buy/Hold, $1.62)
At the time of launch of Surfaxin on November 8, 2013 Discovery Laboratory’s (DSCO) stock was selling at $2.00.…
Discovery Laboratories: A Look at the Surfaxin Launch and the Phase 2a Trial of Aerosurf (DSCO, Buy, $1.79, free content)
Launch of Surfaxin
The launch of Surfaxin has begun and initial results were below expectations causing the Company a few months…
I have just published the first of a series of reports on Discovery Laboratories.
Discovery Laboratories: What the Marketing Approval of Surfaxin Could Mean to the Stock (DSCO, $2.72)
Surfaxin is Finally Cleared for Commercialization in the US